We report two cases of severe hypertriglyceridaemia associated with human immunode ciency virus infection and highly active antiretroviral therapy (HAART). The rst patient, a 39-year-old man, developed moderate hypertriglyceridaemia (5 ¢ 88 mmol/L) and hypercholesterolaemia (7 ¢ 0 mmol/L) after 8 months of HAART. When his therapy was altered, triglyceride and cholesterol concentrations increased further to 15 ¢ 9 and 10 ¢ 9 mmol/L, respectively, after 6 weeks. The second patient, a 31-year-old man, presented with triglyceride and cholesterol concentrations of 16 ¢ 2 and 5 ¢ 7 mmol/L, respectively, following an 8-year history of HAART. Therapy was changed, but 1 month later the triglyceride concentration had increased to 39 ¢ 4 mmol/L and the cholesterol concentration to 12 ¢ 1 mmol/L. Both patients were managed by a change in HAART and the introduction of a bric acid derivative. Although neither patient displayed any clinical symptoms associated with hypertriglyceridaemia, it is important to recognize such cases because of the associated risk of pancreatitis and coronary disease.
Introduction
The standard therapy for human immunode¢ciency virus (HIV) infection is known as highly active antiretroviral therapy (HAART), which is a combination of antiviral drugs selected from reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors. HAART acts to signi¢cantly reduce the viral load but does not eradicate it. Prior to the introduction of HAART, an association of both HIV and acquired immune de¢ciency syndrome (AIDS) with hypertriglyceridaemia had been documented. 1, 2 Subsequently, it was reported that antiretroviral drugs, in particular the protease inhibitors, are independently associated with a small but signi¢cant mean rise in the concentration of both triglycerides (1¢1 mmol/ L) and total cholesterol (0¢73 mmol/ L). 3, 4 Markedly elevated triglyceride concentrations (410 mmol/ L) have been reported in a small number of patients, and pancreatitis 5^10 and premature myocardial infarction 10, 11 were complications in some of these cases. We report two new cases of severe hypertriglyceridaemia that responded to a change in HAART and/or lipidlowering drugs.
Case 1
A 39-year-old man presented in January 1999 with a year-long history of weight loss (6¢4 kg), intermittent diarrhoea, a persistent sore throat and £orid eczema. He was found to be HIV-positive, severely immunocompromised with a low CD4 count (58 cells/mm 3 ; reference range 510^1074 cells/mm 3 ) and a viral load of 1100 000 copies/mL. The viral load, which acts as a marker of viral replication, is used to monitor patients during therapy with the aim to reduce the viral load as much as possible.
The patient was started on the following regimen of HAART: the protease inhibitor nel¢navir, and the nucleoside analogues lamivudine (3TC) and stavudine (d4T). On assessment 3 months later, there was a marked improvement in general health and a gain in weight. The patient's CD4 count had increased to 177 cells/mm 3 and the HIV was suppressed to an undetectable level. However, in July 1999, he presented with a mild degree of peripheral neuropathy and complained of an overall deterioration in general health and a persistent tiredness. By the end of August, the viral load was again detectable (2000 copies/mL) and the CD4 count had fallen (122 cells/mm 3 ). Biochemical investigations showed a triglyceride concentration of 5¢88 mmol/ L and a cholesterol concentration of 7¢0 mmol/ L. Drug compliance was considered to be satisfactory and on 21 September 1999 the therapy was changed to the protease inhibitors ritonavir and indinavir, and the nucleoside analogue zidovudine (AZT). Two weeks into this new regimen the patient was feeling well, the CD4 count had increased (222 cells/mm 3 ) and the virus was not detectable. As planned, the nucleoside reverse transcriptase inhibitor didanosine (DDI) was added to the regimen 6 weeks later, once the peripheral neuropathy had settled (peripheral neuropathy is a potential side-e¡ect of DDI). The following day a marked increase in the triglyceride and cholesterol concentrations was noted (15¢9 and 10¢9 mmol/ L, respectively). The hyperlipidaemia was managed ¢rst by alteration of the therapy and then by introduction of the lipid-lowering drug beza¢brate and a carbohydrate-restricted and alcohol-free diet. DDI was omitted from the regimen as it is associated with pancreatitis, the ritonavir dose was reduced (from 400 mg b.d. to 100 mg b.d.) and the inidinavir dose was increased (from 400 mg b.d. to 800 mg b.d.). Compliance with this diet was considered satisfactory and a response to the therapy was seen after only 1 week, with a fall of cholesterol concentration to 7¢9 mmol/ L and a fall of triglyceride concentration to 8¢8 mmol/ L, which has since been maintained. Abacavir was subsequently added to this therapy with no adverse response. It should be noted that at no time did the patient show any clinical evidence of pancreatitis or lipodystrophy and his blood glucose remained stable throughout.
Case 2
A 31-year-old man was found to be HIV-positive in April 1990. Over the next 8 years he was treated with various antiretroviral combinations, including AZT, DDI, 3TC, d4T, saquinavir, ritonavir and nevirapine. In March 1998 the antiretroviral therapy consisted of d4T, saquinavir and ritonavir. The patient was noted to have a viral load of 63100 copies/mL and a blood glucose concentration of 23¢3 mmol/ L; other biochemical tests were within their respective reference ranges. Prior to this particular combination of therapy the patient was not known to be diabetic. The therapy was therefore changed to two nucleoside reverse transcriptase inhibitors, d4T and DDI, and nevirapine, a non-nucleoside reverse transcriptase inhibitor. The viral load steadily increased and in October 1999 the regimen was changed to AZT, zalcitabine (DDC) and efavirenz; again, no protease inhibitor was prescribed. One month later a peripheral neuropathy had developed and the biochemistry results were cholesterol 5¢7 mmol/ L, triglycerides 16¢2 mmol/ L and glucose 7¢0 mmol/L. The drug combination was changed to 3TC, AZT and hydroxyurea and the cholesterol and triglyceride concentrations fell to 4¢1 mmol/ L and 5¢5 mmol/ L, respectively. In February 2000, the HAART was terminated following an episode of pancytopenia (which required a blood transfusion) and active disease, indicated by an increased viral load (385 000 copies/mL). The following month a new regimen of HAART was introduced: AZT, 3TC and the protease inhibitor nel¢navir.
In September 2000 the patient was found to have a cholesterol concentration of 12¢1mmol/ L, a triglyceride concentration of 39¢4 mmol/ L and a glucose concentration of 6¢6 mmol/ L. He was prescribed beza¢brate and the HAART was stopped. One month later, the cholesterol and triglyceride concentrations had decreased to 5¢3 and 8¢6 mmol/ L, respectively. It is impossible to know whether the decrease in triglyceride concentration was a result of cessation of the HAART, the introduction of beza¢brate or a combination of the two. It should be noted that at no time did the patient display any of the clinical symptoms associated with hypertriglyceridaemia (e.g. pancreatitis). Amylase was monitored throughout and was consistently within the reference range.
Discussion
Some of the adverse e¡ects of protease inhibitors are due to insulin resistance and those of reverse transcriptase inhibitors are due to mitochondrial damage. The adverse e¡ects of nucleoside and nucleotide reverse transcriptase inhibitors are secondary to mitochondrial toxicity due to inhibition of the g subunit of DNA polymerase. 12 The production of ATP by oxidative phosphorylation is disrupted due to the defective synthesis of mitochondrial enzymes. Myopathy, neuropathy, lactic acidaemia and pancreatitis can occur. Abnormalities associated with protease inhibitors include lipodystrophy, hyperlipidaemia and insulin resistance, and it is these disorders that are more relevant to the cases discussed here.
The association between lipid abnormalities and HIV infection has been well studied: HIV is associated with an increase in triglyceride concentration and a decrease in total cholesterol concentration (see Table  1 ). One possible explanation for the hypertriglyceridaemia is the relationship between circulating cytokines and plasma lipids. a-Interferon is positively correlated with plasma triglyceride concentrations: 13, 14 a-interferon concentrations increase as the disease progresses and a¡ect the clearance of triglycerides from the blood. With the introduction of HAART, a syndrome of lipodystrophy, hyperlipidaemia, impaired glucose tolerance, insulin resistance and diabetes has been described. 15 Hyperlipidaemia is the most common side-e¡ect and is characterized by an increase in triglycerides, total cholesterol, VLDL, LDL and a decrease in HDL cholesterol. 16 Symptoms may occur within weeks of starting therapy. 4, 17 The hypertriglyceridaemia associated with HAART was initially thought to be an e¡ect of the protease inhibitors, 13 although recently the nucleoside reverse transcriptase inhibitors have also been implicated. 18 The exact mechanism by which protease inhibitors a¡ect lipid metabolism is not clear. One hypothesis is that the protease inhibitors are structurally similar to the HIV protease enzyme and may act by binding to LDL receptor related protein and cytoplasmic retinoic acid binding protein. As a result, these proteins, which are involved in lipid metabolism, may also be inhibited and lipid metabolism disrupted. 19 In recent years, considerable work has been undertaken in this ¢eld; the results of various studies are summarized in Table 2 .
HAART is highly e¡ective at controlling the progression of HIV infection, so the life-expectancy of HIV-positive patients is likely to increase. As a result, an understanding of the adverse metabolic e¡ects of HAART and their management will be of great importance. Severe hypertriglyceridaemia is associated with an increased risk of pancreatitis and coronary artery disease. To date, there have been at least 17 individual case reports of HIV-positive patients on HAART with hypertriglyceridaemia. Nine of these cases demonstrated severe hypertriglyceridaemia associated with speci¢c clinical symptoms: pancreatitis (nˆ6); 5^10 cardiac events (nˆ2); 10 lipaemia retinalis (nˆ1) 8 and cutaneous xanthoma (nˆ1). 24 Table 3 summarize s the antiretroviral therapy, the post-therapy triglyceride concentrations and the clinical symptoms associated with each of these cases. There were seven reported cases of premature myocardial infarction in patients on HAART who only exhibited moderately elevated triglycerides (range: 1¢58^4¢16 mmol/ L). 10, 11, 25 The remaining report was of a patient on AZT, 3TC and nel¢navir with severe hypertriglyceridaemia (25¢8 mmol/ L) but no associated clinical symptoms, 7 like the two cases we report here.
The very nature of HAART makes it di¤cult to determine which drug is causing the hypertriglyceridaemia because patients are on a combination of drugs. In the ¢rst case described here, although the patient was on both ritonavir and indinavir, the increase in triglycerides appears to coincide with the introduction of a nucleoside reverse transcriptase inhibitor (DDI) to the drug regimen, whereas in the second case it is likely that the hypertriglyceridaemia was due to nel¢navir as the only other drugs the patient was on were AZT and 3TC. These two cases reinforce the fact that, although hypertriglyceridaemia is usually associated with the protease inhibitor ritonavir, other protease inhibitors and nucleoside analogues can also be responsible. Further investigations into the side-e¡ects of HAART are necessary. First-line therapy for hyperlipidaemia will be based on diet and exercise plan. Oral hypolipidaemic agents are used only when these measures fail. However, these agents need to be used with caution in HIV patients as they are metabolized by the hepatic cytochrome P450 system along with protease inhibitors and non-nucleoside reverse transcriptase inhibitors with the potential for interaction. Feno¢brate, a lipidlowering drug, has been used successfully to treat hypertriglyceridaemia, with a reduction of 475% after 10 months in two patients with HAARTassociated hypertriglyceridaemia. 7 This experience is similar to that reported in the cases discussed here.
In summary, HAART is associated with an increase in plasma lipids, which is usually modest but in some cases may be quite extreme and can lead to serious complications such as pancreatitis, coronary heart disease and lipaemia retinalis (see Table 3 ). Early recognition may reduce the risk of these complications.
